Trials / Conditions / Childhood Grade III Meningioma

Childhood Grade III Meningioma

13 registered clinical trials studyying Childhood Grade III Meningioma.

Status	Trial	Sponsor	Phase
Terminated	Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervou NCT02255461	Pediatric Brain Tumor Consortium	Phase 1
Withdrawn	Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors NCT02194452	Sue O'Dorisio	N/A
Terminated	Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS T NCT01088763	National Cancer Institute (NCI)	Phase 1
Completed	Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spi NCT01076530	National Cancer Institute (NCI)	Phase 1
Completed	ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors NCT00946335	National Cancer Institute (NCI)	Phase 1
Completed	Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma NCT00363272	National Cancer Institute (NCI)	Phase 1
Completed	AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors NCT00326664	National Cancer Institute (NCI)	Phase 1
Completed	Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors NCT00100880	National Cancer Institute (NCI)	Phase 1
Completed	Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors NCT00919750	Children's Oncology Group	—
Completed	Cilengitide in Treating Children With Refractory Primary Brain Tumors NCT00063973	National Cancer Institute (NCI)	Phase 1
Completed	Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors NCT00052780	National Cancer Institute (NCI)	Phase 1
Completed	FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia NCT00053963	National Cancer Institute (NCI)	Phase 1
Completed	Irinotecan in Treating Children With Refractory Solid Tumors NCT00004078	Children's Oncology Group	Phase 2